CAT exclusively licenses Debiopharm Ab
UK-based Cambridge Antibody Technology has signed a deal an exclusive worldwide licensing agreement to develop and commercialize SC-1, a fully-human antibody that targets a cell surface receptor specifically expressed on gastric carcinoma cells, with Switzerland's Debiopharm.
SC-1 was developed by Debiopharm, a global independent biopharmaceutical company specializing in oncology and serious medical conditions, for the treatment of gastric carcinoma. Under the terms of the deal, Debiopharm will receive upfront and milestone payments from CAT, which is owned by Anglo-Swedish drug major AstraZeneca, as well as royalties on potential future sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze